What is Elucid?
Elucid is at the forefront of medical technology, developing AI-powered solutions designed to optimize treatment decisions for patients with cardiovascular disease. The company's proprietary technology offers physicians cost-effective, interpretable, and validated AI insights, enabling precision medicine. Elucid's non-invasive software is the first of its kind to be FDA-Cleared and CE-marked for quantifying atherosclerotic plaque characteristics against histopathology, including Lipid Rich Necrotic Core, providing critical clinical information for advanced patient care.
How much funding has Elucid raised?
Elucid has raised a total of $45.2M across 3 funding rounds:
Grant
$696K
Series A
$8M
Private Equity
$36.5M
Grant (2014): $696K with participation from National Science Foundation
Series A (2021): $8M led by University of Michigan, MedTex Ventures, IAG Capital Partners, Willamette Valley Capital, BlueStone Venture Partners, Checkmate Capital, Angel Physicians Fund, and Global Health Impact Fund
Private Equity (2025): $36.5M, investors not publicly disclosed
Key Investors in Elucid
IAG Capital Partners
IAG Capital Partners is a venture capital firm specializing in leading investment rounds from seed to Series C, operating from Charleston, SC, and London, UK. They focus on providing financial support to innovative companies at various stages of their development.
Willamette Valley Capital
Willamette Valley Capital is a deep tech venture capital firm focused on building a better world through innovative investments, operating on a referral and invitation-only basis for accredited investors. Their mission is to support transformative technologies.
BlueStone Venture Partners
BlueStone Venture Partners is a life sciences venture capital fund investing in innovative companies outside traditional hubs, particularly in the Southwest. They aim to support entrepreneurial ventures in life sciences and information technology.
What's next for Elucid?
With the recent major strategic investment, Elucid is poised for accelerated growth and market expansion. The company is expected to further refine its AI algorithms and broaden the clinical applications of its diagnostic tools. This enterprise-level funding will likely support enhanced research and development initiatives, strategic partnerships, and the scaling of its commercial operations to reach a wider patient and physician base. Elucid's focus on precision medicine and cost-effective solutions positions it for significant impact in the cardiovascular health sector.
See full Elucid company page
